Moody Aldrich Partners LLC Boosts Stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

Moody Aldrich Partners LLC grew its holdings in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 142.5% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 163,483 shares of the company's stock after acquiring an additional 96,068 shares during the period. Protagonist Therapeutics comprises approximately 1.7% of Moody Aldrich Partners LLC's holdings, making the stock its 12th largest position. Moody Aldrich Partners LLC owned about 0.27% of Protagonist Therapeutics worth $7,906,000 as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of PTGX. Arrowstreet Capital Limited Partnership boosted its holdings in Protagonist Therapeutics by 36.7% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 216,069 shares of the company's stock worth $8,340,000 after buying an additional 58,002 shares during the period. Charles Schwab Investment Management Inc. boosted its holdings in Protagonist Therapeutics by 2.3% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 578,409 shares of the company's stock worth $22,327,000 after buying an additional 12,906 shares during the period. GAMMA Investing LLC boosted its holdings in Protagonist Therapeutics by 12,147.8% in the 1st quarter. GAMMA Investing LLC now owns 58,177 shares of the company's stock worth $2,813,000 after buying an additional 57,702 shares during the period. Victory Capital Management Inc. boosted its holdings in Protagonist Therapeutics by 84.1% in the 4th quarter. Victory Capital Management Inc. now owns 240,817 shares of the company's stock worth $9,296,000 after buying an additional 110,020 shares during the period. Finally, Teacher Retirement System of Texas boosted its holdings in Protagonist Therapeutics by 18.7% in the 4th quarter. Teacher Retirement System of Texas now owns 13,099 shares of the company's stock worth $506,000 after buying an additional 2,067 shares during the period. Institutional investors own 98.63% of the company's stock.

Protagonist Therapeutics Price Performance

Shares of NASDAQ:PTGX traded down $1.18 on Monday, hitting $49.87. 771,742 shares of the company's stock were exchanged, compared to its average volume of 843,650. The stock has a market capitalization of $3.09 billion, a price-to-earnings ratio of 66.49 and a beta of 2.26. The business's 50 day simple moving average is $49.40 and its two-hundred day simple moving average is $44.69. Protagonist Therapeutics, Inc. has a 12 month low of $32.50 and a 12 month high of $60.60.

Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) last issued its earnings results on Tuesday, May 6th. The company reported ($0.19) EPS for the quarter, topping analysts' consensus estimates of ($0.50) by $0.31. The business had revenue of $28.32 million for the quarter, compared to analyst estimates of $30.44 million. Protagonist Therapeutics had a net margin of 27.04% and a return on equity of 9.22%. Equities analysts forecast that Protagonist Therapeutics, Inc. will post 2.43 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages recently weighed in on PTGX. Truist Financial upped their target price on shares of Protagonist Therapeutics from $60.00 to $76.00 and gave the stock a "buy" rating in a report on Tuesday, March 11th. BMO Capital Markets increased their price objective on shares of Protagonist Therapeutics from $62.00 to $72.00 and gave the company an "outperform" rating in a report on Tuesday, March 11th. Wedbush reissued an "outperform" rating and set a $70.00 price objective on shares of Protagonist Therapeutics in a report on Friday, March 28th. Citigroup started coverage on shares of Protagonist Therapeutics in a report on Tuesday, June 17th. They set a "buy" rating and a $72.00 price objective for the company. Finally, HC Wainwright reissued a "buy" rating and set a $80.00 price objective on shares of Protagonist Therapeutics in a report on Tuesday, June 3rd. Two equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $66.10.

Insider Activity at Protagonist Therapeutics

In other Protagonist Therapeutics news, CFO Asif Ali sold 1,756 shares of Protagonist Therapeutics stock in a transaction on Tuesday, April 22nd. The shares were sold at an average price of $46.00, for a total value of $80,776.00. Following the transaction, the chief financial officer directly owned 61,065 shares of the company's stock, valued at approximately $2,808,990. The trade was a 2.80% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Arturo Md Molina sold 10,000 shares of the business's stock in a transaction on Tuesday, June 10th. The shares were sold at an average price of $57.03, for a total transaction of $570,300.00. Following the sale, the insider directly owned 83,892 shares in the company, valued at $4,784,360.76. This trade represents a 10.65% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 4.90% of the company's stock.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.